These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 9933673)
61. Characterization of hyperintense nodules on T1-weighted liver magnetic resonance imaging: comparison of Ferucarbotran-enhanced MRI with accumulation-phase FS-T1WI and gadolinium-enhanced MRI. Chou CT; Chen RC; Chen WT; Lii JM J Chin Med Assoc; 2011 Feb; 74(2):62-8. PubMed ID: 21354082 [TBL] [Abstract][Full Text] [Related]
62. Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver: correlation with MR imaging and angiographically assisted CT. Kanematsu M; Osada S; Amaoka N; Goshima S; Kondo H; Moriyama N Abdom Imaging; 2006; 31(1):78-89. PubMed ID: 16317488 [TBL] [Abstract][Full Text] [Related]
64. Differentiation of well-differentiated hepatocellular carcinomas from other hepatocellular nodules in cirrhotic liver: value of SPIO-enhanced MR imaging at 3.0 Tesla. Park HS; Lee JM; Kim SH; Chang S; Kim SJ; Han JK; Choi BI J Magn Reson Imaging; 2009 Feb; 29(2):328-35. PubMed ID: 19161184 [TBL] [Abstract][Full Text] [Related]
66. Guidelines for imaging focal lesions in liver cirrhosis. Lencioni R; Crocetti L; Della Pina MC; Cioni D Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):697-703. PubMed ID: 19072346 [TBL] [Abstract][Full Text] [Related]
67. Small hyperintense hepatic lesions on T1-weighted images in patients with cirrhosis: evaluation with serial MRI and imaging features for clinical benignity. Shimizu A; Ito K; Sasaki K; Hayashida M; Tanabe M; Shimizu K; Matsunaga N Magn Reson Imaging; 2007 Dec; 25(10):1430-6. PubMed ID: 17524587 [TBL] [Abstract][Full Text] [Related]
68. Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Ward J; Guthrie JA; Scott DJ; Atchley J; Wilson D; Davies MH; Wyatt JI; Robinson PJ Radiology; 2000 Jul; 216(1):154-62. PubMed ID: 10887242 [TBL] [Abstract][Full Text] [Related]
69. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Forner A; Vilana R; Ayuso C; Bianchi L; Solé M; Ayuso JR; Boix L; Sala M; Varela M; Llovet JM; Brú C; Bruix J Hepatology; 2008 Jan; 47(1):97-104. PubMed ID: 18069697 [TBL] [Abstract][Full Text] [Related]
70. Hepatic nodules in Budd-Chiari syndrome: imaging features. Vilgrain V; Lewin M; Vons C; Denys A; Valla D; Flejou JF; Belghiti J; Menu Y Radiology; 1999 Feb; 210(2):443-50. PubMed ID: 10207428 [TBL] [Abstract][Full Text] [Related]
71. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Willatt JM; Hussain HK; Adusumilli S; Marrero JA Radiology; 2008 May; 247(2):311-30. PubMed ID: 18430871 [TBL] [Abstract][Full Text] [Related]
72. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis. Park MJ; Kim YK; Lee MH; Lee JH Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300 [TBL] [Abstract][Full Text] [Related]
73. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. de Lédinghen V; Laharie D; Lecesne R; Le Bail B; Winnock M; Bernard PH; Saric J; Couzigou P; Balabaud C; Bioulac-Sage P; Drouillard J Eur J Gastroenterol Hepatol; 2002 Feb; 14(2):159-65. PubMed ID: 11981340 [TBL] [Abstract][Full Text] [Related]
74. Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis. Iavarone M; Manini MA; Sangiovanni A; Fraquelli M; Forzenigo LV; Di Tommaso L; Aghemo A; Roncalli M; Ronchi G; Colombo M Dig Liver Dis; 2013 Jan; 45(1):43-9. PubMed ID: 23022425 [TBL] [Abstract][Full Text] [Related]
75. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092 [TBL] [Abstract][Full Text] [Related]
76. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Kim JI; Lee JM; Choi JY; Kim YK; Kim SH; Lee JY; Han JK; Choi BI Invest Radiol; 2008 Mar; 43(3):202-10. PubMed ID: 18301317 [TBL] [Abstract][Full Text] [Related]
77. Pitfalls in the imaging diagnosis of hepatocellular nodules in the cirrhotic and noncirrhotic liver. Yoshimitsu K; Irie H; Aibe H; Tajima T; Nishie A; Asayama Y; Matake K; Nakayamka T; Kakihara D; Honda H Intervirology; 2004; 47(3-5):238-51. PubMed ID: 15383733 [TBL] [Abstract][Full Text] [Related]
78. Clinical implication of small (<20 mm) enhancing hepatic nodules observed only during three-dimensional gadobenate dimeglumine-enhanced hepatic arterial-phase MRI of the hepatitis B virus-induced mild cirrhosis. Kim YK; Lee YH; Kwak HS; Kim CS; Han YM Clin Imaging; 2008; 32(6):453-9. PubMed ID: 19006774 [TBL] [Abstract][Full Text] [Related]
79. Diagnosing Borderline Hepatic Nodules in Hepatocarcinogenesis: Imaging Performance. Choi BI; Lee JM; Kim TK; Dioguardi Burgio M; Vilgrain V AJR Am J Roentgenol; 2015 Jul; 205(1):10-21. PubMed ID: 26102378 [TBL] [Abstract][Full Text] [Related]
80. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. Di Martino M; Marin D; Guerrisi A; Baski M; Galati F; Rossi M; Brozzetti S; Masciangelo R; Passariello R; Catalano C Radiology; 2010 Sep; 256(3):806-16. PubMed ID: 20720069 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]